Cholangiocarcinoma Treatment Market: How Is FGFR2-Targeted Therapy...

ha aggiunto una foto Health

2026-06-26 10:43:46 -

Cholangiocarcinoma Treatment Market: How Is FGFR2-Targeted Therapy Redefining First-Line Precision Medicine in Bile Duct Cancer?

FGFR2-targeted therapy — the biomarker-driven treatment paradigm where pemigatinib demonstrated a 42% reduction in disease progression risk versus standard chemotherapy in the Phase 3 FIGHT-302 trial, establishing the first potential first-line targeted therapy for FGFR2 fusion-positive cholangiocarcinoma — creates the most clinically transformative market dynamic, with the...

0 Commenti 0 condivisioni 19 Views 0 Anteprima